Dexibuprofen

Summary

Dexibuprofen (CHEMBL175) is an approved small-molecule non-narcotic analgesic (ATC M01AE14); indicated across 3 conditions including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M01AE14
• Indications: 3 conditions
• Clinical trials: 6
• Chemistry: 206.28 Da · C13H18O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL175
Name	Dexibuprofen
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	39912
ChEBI	CHEBI:43415
ATC	M01AE14
Molecular formula	C13H18O2
Molecular weight	206.28
InChIKey	HEFNNWSXXWATRW-JTQLQIEISA-N

SMILES: C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O

IUPAC name: (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid

Pharmacological roles (ChEBI): non-narcotic analgesic, non-steroidal anti-inflammatory drug.

Also known as: (s)-ibuprofen, Dexibuprofen, Dexibuprofene, Dexibuprofeno, NSC-759814, S-ibuprofen, Seractil, (S)-ibuprofen, S(+)-Ibuprofen, SID11111293, SID11111294, SID11112775

Parent form; salt/anhydrous children: CHEMBL1778537

Patent coverage: 3,300 distinct patent families (12,118 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 12,114 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Prelamin-A/C, RecQ-like DNA helicase BLM, Endonuclease 4, Peripheral myelin protein 22, Thyrotropin receptor, Interleukin-8 receptors, CXCR1/CXCR2, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1, Cytochrome P450 2C9.

Bioactivity

ChEMBL activities: 18 potent at pChembl ≥ 5 of 27 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
BLM	8.55	Potency	2.8	nM	CHEMBL_ACT_4742002
BLM	8.55	Potency	2.8	nM	CHEMBL_ACT_4913956
PTGS1	7.01	IC50	98.65	nM	CHEMBL_ACT_8017611
CXCR1	7	IC50	100	nM	CHEMBL_ACT_1492270
PTGS1	6.98	IC50	105	nM	CHEMBL_ACT_7685382
P0A6C1	6.6	Potency	251.2	nM	CHEMBL_ACT_4084644
PTGS2	6.14	IC50	730	nM	CHEMBL_ACT_8017613
P05979	5.83	IC50	1480	nM	CHEMBL_ACT_8017741
P79208	5.82	IC50	1500	nM	CHEMBL_ACT_3436572
P05979	5.65	IC50	2260	nM	CHEMBL_ACT_777586
PTGS2	5.61	IC50	2460	nM	CHEMBL_ACT_22789191
LMNA	5.6	Potency	2512	nM	CHEMBL_ACT_3644595
TSHR	5.6	Potency	2512	nM	CHEMBL_ACT_3921019
TSHR	5.6	Potency	2512	nM	CHEMBL_ACT_4618229
PTGS1	5.58	IC50	2600	nM	CHEMBL_ACT_2460290
P05979	5.5	IC50	3200	nM	CHEMBL_ACT_3436604
P05979	5.35	IC50	4500	nM	CHEMBL_ACT_22789174
P05979	5.3	IC50	4960	nM	CHEMBL_ACT_22789241

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	3
PHASE4	1
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01066676	PHASE4	COMPLETED	Dexibuprofen 400 mg Sachet Versus Ibuprofen 400 mg Sachet in Patients With Osteoarthritis of the Hip or Knee
NCT00812422	PHASE3	COMPLETED	The Efficacy and Safety of Dexibuprofen Syrup
NCT03852459	PHASE2	COMPLETED	Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS
NCT00442585	PHASE1	COMPLETED	S(+)-Ibuprofen Effects on Asprin Treated Volunteers
NCT02956512	PHASE1	COMPLETED	Phase I Study to Evaluate the Safety of Dexibuprofen 300mg Under Fasting and Fed Conditions
NCT02956525	PHASE1	COMPLETED	Phase I Study to Evaluate the Safety of Dexibuprofen 200mg Under Fasting and Fed Conditions

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).